AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

20 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

13 Feb 2025 06:31:00 By Nasdaq GlobeNewswire

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

13 Feb 2025 06:30:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

06 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

03 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

18 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

08 Dec 2024 12:40:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

11 Nov 2024 09:45:31 By NetDania Notify

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

08 Nov 2024 09:55:39 By NetDania Notify

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

07 Nov 2024 14:59:27 By NetDania Notify

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

05 Nov 2024 09:05:00 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

31 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

17 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

26 Sep 2024 09:45:10 By NetDania Notify

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

11 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

06 Aug 2024 17:50:17 By Nasdaq GlobeNewswire